Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease

Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J George, Michael R Harrison, Terence Z Wong, Andrew J Armstrong, Daniel J George

Abstract

Background: Radium-223 chloride ((223)Ra; Alpharadin) is an alpha-emitting radioisotope that targets areas of osteoblastic metastasis and is excreted by the small intestine. When compared with beta-emitters (eg, strontium-89, samarium-153), (223)Ra delivers a high quantity of energy per track length with short tissue penetration.

Objective: This review describes the mechanism, radiobiology, and preclinical development of (223)Ra and discusses the clinical data currently available regarding its safety and efficacy profile.

Methods: Data from clinical trials including abstracts were collected and reviewed using the PubMed Database, as well as the American Society of Clinical Oncology abstract database.

Conclusion: Current bone-targeted therapies fall into two main categories: antiresorptive agents (eg, zoledronic acid, denosumab), which have been shown to delay skeletal-related events, and radiopharmaceuticals (eg, samarium-153), which may have a role in pain palliation. Historically, neither antiresorptive agents nor radiopharmaceuticals have shown definitive evidence of improved overall survival or other antitumor effects in metastatic castrate-resistant prostate cancer (mCRPC). Radiopharmaceuticals are limited by myelosuppresion, thrombocytopenia, and renal excretion. In a recently reported randomized Phase III trial in men with symptomatic bone-metastatic CRPC who had received or were ineligible for docetaxel chemotherapy, (223)Ra treatment resulted in improved overall survival and delayed skeletal-related events. Toxicity consisted of minor gastrointestinal side effects and mild neutropenia and thrombocytopenia that were rarely severe. Pending regulatory approval, (223)Ra may represent a unique and distinct option for an important subgroup of patients with mCRPC; future trials should address its use in combination or in sequence with existing and novel agents.

Keywords: 223Ra; Alpharadin; bone metastases; metastatic castrate-resistant prostate cancer; radionuclide therapy; radium-223.

Figures

Figure 1
Figure 1
Mechanism of action for the targeting of osseous metastases by 223Ra. Reprinted with permission from Algeta ASA, from 2012 ASCO GU Symposium presentation. Abbreviation:223Ra, radium-223.

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
    1. Josson S, Matsuoka Y, Chung LW, Zhau HE, Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin Cell Dev Biol. 2010;21(1):26–32.
    1. Armstrong AJ, Marengo MS, Oltean S, et al. Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers. Mol Cancer Res. 2011;9(8):997–1007.
    1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520.
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512.
    1. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396–6403.
    1. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol. 2007;25(25):3965–3970.
    1. Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203–211.
    1. Halabi S, Vogelzang NJ, Kornblith AB, et al. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008;26(15):2544–2549.
    1. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14(6):1756–1764.
    1. Roque IFM, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011;7:CD003347.
    1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147–1154.
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995–2005.
    1. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94(19):1458–1468.
    1. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813–822.
    1. Scher HI, Fizazi K, Saad F, et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol. 2012;30(Suppl 5) Abstr LBA1.
    1. de Bono J, Fizazi K, Saad F, et al. Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor. J Clin Oncol. 2012;30(Suppl) Abstr 4519.
    1. Enzalutamide (XTANDI Capsules) [webpage on the Internet] Silver Spring, MD: US Food and Drug Administration; 2012. [Accessed December 12, 2012]. [updated September 4, 2012]. Available from: .
    1. Logothetis C, De Bono JS, Molina A, et al. Effect of abiraterone acetate (AA) on pain control and skeletal-related events (SRE) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) post docetaxel (D): Results from the COU-AA-301 phase III study. J Clin Oncol. 2011;29(Suppl) Abstr 4520.
    1. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96(11):879–882.
    1. Adam A, Dixon AK, Allison DJ, Grainger RG. Grainger and Allison’s Diagnostic Radiology: a Textbook of Medical Imaging. 5th ed. Edinburgh: Churchill Livingstone; 2008.
    1. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer. 1991;27(8):954–958.
    1. Buchali K, Correns HJ, Schuerer M, Schnorr D, Lips H, Sydow K. Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma. Eur J Nucl Med. 1988;14(7–8):349–351.
    1. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–813.
    1. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31(1):33–40.
    1. Oosterhof GO, Roberts JT, de Reijke TM, et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol. 2003;44(5):519–526.
    1. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574–1581.
    1. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940–945.
    1. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109(3):637–643.
    1. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436–2442.
    1. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357(9253):336–341.
    1. Sciuto R, Festa A, Rea S, et al. Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43(1):79–86.
    1. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 2009;27(15):2429–2435.
    1. Parker C, Heinrich D, O’Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha- pharmaceutical: results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30(Suppl 5) Abstr 8.
    1. Bayer . ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. Radium-223 Chloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients with Bone Metastases. [updated September 20, 2012]. Available from: . NLM identifier: NCT01516762.
    1. Perez CA. Principles and Practice of Radiation Oncology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2004.
    1. Bruland ØS, Nilsson S, Fisher DR, Larsen RH. High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? Clin Cancer Res. 2006;12(20 Pt 2):6250s–6257s.
    1. Blake GM, Gray JM, Zivanovic MA, McEwan AJ, Fleming JS, Ackery DM. Strontium-89 radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol. 1987;60(715):685–692.
    1. Breen SL, Powe JE, Porter AT. Dose estimation in strontium-89 radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992;33(7):1316–1323.
    1. Bone curriculum. American Society of Bone and Mineral Research; [Accessed July 26, 2012]. ASBMR educational materials [webpage on the Internet] Available from: . [updated 2008]
    1. Tiepolt C, Gruning T, Franke WG. Renaissance of 224 Ra for the treatment of ankylosing spondylitis: clinical experiences. Nucl Med Commun. 2002;23(1):61–66.
    1. Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11(12):4451–4459.
    1. Ritter MA, Cleaver JE, Tobias CA. High-LET radiations induce a large proportion of non-rejoining DNA breaks. Nature. 1977;266(5603):653–655.
    1. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
    1. Henriksen G, Fisher DR, Roeske JC, Bruland OS, Larsen RH. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44(2):252–259.
    1. Henriksen G, Breistol K, Bruland OS, Fodstad O, Larsen RH. Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model. Cancer Res. 2002;62(11):3120–3125.
    1. Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys. 2003;56(5):1397–1404.
    1. Nilsson S, Balteskard L, Fossa SD, et al. Phase I study of Alpharadin2 (223Ra), and a-emitting bone-seeking agent in cancer patients with skeletal metastases. EurJ Nucl Med Mol Imaging. 2004;31(S2):S290. Abstract 370.
    1. Carrasquillo JA, Donoghue JAO, Pandit-Taskar N, et al. Phase I pharmacokinetic (PK) and biodistribution study of radium-223 chloride in patients with castration resistant prostate cancer (CRPC) metastatic to bone. J Clin Oncol. 2010;28(15s) Abstr 4680.
    1. Nilsson S, Franzen L, Parker C, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol. 2007;8(7):587–594.
    1. Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678–686.
    1. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17(11):3461–3467.
    1. Nilsson S, Franzén L, Parker C, et al. Alpha-emitting radium-223: Two years follow up from a randomized phase II study in patients with bone metastases from hormone refractory prostate cancer. Eur J Cancer Suppl. 2009;7:411. Abstract P-7018.
    1. Nilsson S, O’Bryan-Tear CG, Bolstad B, Lokna A, Parker C. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with Radium-223 (Alpharadin™) J Clin Oncol. 2011;29(Suppl) Abstr 4620.
    1. Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
    1. Palliative Care: Symptom Management and End-of-Life Care. Geneva: World Health Organization; 2004. Available from: . Accessed.
    1. Algeta ASA. ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. A Dose Finding Study of Radium-223 for Prostate Cancer Patients with Bone Metastases. [updated September 8, 2010]. Available from: . NLM identifier: NCT00337155.
    1. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80–100.
    1. Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854–4861.
    1. Sartor AO, Heinrich D, Helle SI, et al. Radium-223 chloride impact on skeletal-related events in patients with castration-resistant prostate cancer (CRPC) with bone metastases: A phase III randomized trial (ALSYMPCA) J Clin Oncol. 2012;30(Suppl 5) Abstr 9.
    1. Loblaw A, Mitera G. Malignant extradural spinal cord compression in men with prostate cancer. Curr Opin Support Palliat Care. 2011;5(3):206–210.
    1. Ryan CJ, Smith MR, De Bono JS, et al. Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) J Clin Oncol. 2012;30(Suppl) Abstr LBA4518.
    1. Medivation Inc. ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients with Progressive Metastatic Prostate Cancer (PREVAIL) [updated October 11, 2012]. Available from: . NLM identifier: NCT01212991.
    1. Italiano A, Ortholan C, Oudard S, et al. Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol. 2009;55(6):1368–1375.
    1. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242–245.
    1. Nekolla EA, Kellerer AM, Kuse-Isingschulte M, Eder E, Spiess H. Malignancies in patients treated with high doses of radium-224. Radiat Res. 1999;152(Suppl 6):S3–S7.
    1. Kossman SE, Weiss MA. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate. Cancer. 2000;88(3):620–624.
    1. Saylor PJ, Lee RJ, Smith MR. Emerging therapies to prevent skeletal morbidity in men with prostate cancer. J Clin Oncol. 2011;29(27):3705–3714.
    1. Bristol-Myers Squibb. ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-Resistant Prostate Cancer (READY) [updated October 5, 2012]. Available from: . NLM identifier: NCT00744497.
    1. Hussain M, Smith MR, Sweeney C, et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol. 2011;29(Suppl) Abstr 4516.
    1. ClinicalTrials gov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. Exelixis Study of Cabozantinib (XL184) Versus Prednisone in Men with Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone or MDV3100 (COMET-1) [updated October 2, 2012]. Available from: . NLM identifier: NCT01605227.
    1. ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. Exelixis Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men with Previously Treated Symptomatic Castration-resistant Prostate Cancer (COMET-2) [updated October 11, 2012]. Available from: . NLM identifier: NCT01522443.
    1. Algeta ASA. ClinicalTrialsgov [website on the Internet] Bethesda, MD: US National Library of Medicine; 2012. [Accessed November 1, 2012]. A Study of Alpharadin® with Docetaxel in Patients with Bone Metastasis From Castration-Resistant Prostate Cancer (CRPC) [updated May 11, 2012]. Available from: . NLM identifier: NCT01106352.
    1. DeWeese TL, Song DY. Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate. Urology. 2000;55(2):169–174.
    1. Quadramet® (samarium Sm 153 lexidronam injection) [prescribing information] Langhorne, PA: EUSA Pharma (USA) Inc; 2009.
    1. Metastron™ (strontium-89 chloride injection) [prescribing information] Arlington Heights, IL: GE Healthcare; 2006.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera